Symbio Pharma (4582 JP) -Â Gross Margin Expansion Led Operational Turnaround in 2021
2020 – an inflection point for Symbio Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
225 Views
SymBio Pharmaceuticals - Licence agreement for IONSYS terminated
The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in...
122 Views
SymBio Pharmaceuticals - Licence agreement for IONSYS terminated
The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in...
100 Views
SymBio Pharmaceuticals - New formulations extend Treakisym patent life
SymBio has substantially increased the value of its Treakisym franchise through in-licensing novel bendamustine formulations from Eagle...
94 Views
New formulations extend Treakisym patent life
SymBio has substantially increased the value of its Treakisym franchise through in-licencing novel bendamustine formulations from Eagle...
160 Views